Expression of integrin-binding protein Nischarin in metastatic breast cancer

Chen,Jie; Feng,Wei‑Liang; Mo,Wen‑Ju; Ding,Xiao‑Wen; Xie,Shang‑Nao

doi:10.3892/mmr.2015.3373

Expression of integrin-binding protein Nischarin in metastatic breast cancer

Authors:
- Jie Chen
- Wei‑Liang Feng
- Wen‑Ju Mo
- Xiao‑Wen Ding
- Shang‑Nao Xie
View Affiliations

Affiliations: Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: February 18, 2015 https://doi.org/10.3892/mmr.2015.3373
Pages: 77-82
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of Nischarin protein in primary breast cancer (PBC), and to evaluate its role in tumor metastasis. Paired specimens of breast cancer tissues and adjacent normal tissues were surgically obtained from 60 patients with PBC at the Zhejiang Cancer Hospital (Hangzhou, China). Nischarin protein concentrations were determined by an ELISA assay. Breast cancer tissues exhibited a significantly lower concentration of Nischarin (5.86±3.19 ng/ml) compared with that of the adjacent noncancerous tissues (9.25±3.65 ng/ml; P<0.001). Furthermore, cancer tissue from patients with lymph node metastasis had significantly lower levels of Nischarin protein (4.69±2.40 ng/ml) than those of patients without lymph node metastasis (7.04±3.47 ng/ml; P=0.004). There was no significant difference in Nischarin protein expression levels between patients with grade I, II or III PBC (grade I, 5.44±3.57 ng/ml; grade II, 6.42±3.85 ng/ml and grade III, 5.10±1.18 ng/ml; P=0.765). The significant differences in the expression of Nischarin between: i) Cancer tissue and noncancerous tissue and ii) patients with and without lymph node metastasis, suggested that Nischarin may have a significant role in tumor occurrence and metastasis of breast cancer. Nischarin expression may therefore be used as a marker to predict the invasiveness and metastasis of PBC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
3	Perez EA, Romond EH, Suman VJ, et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 32:3744–3752. 2014. View Article : Google Scholar : PubMed/NCBI
4	Albain KS, Barlow WE, Ravdin PM, et al: Breast Cancer Intergroup of North America: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 374:2055–2063
5	Clarke M, Collins R, Darby S, et al: Early Breast Cancer Trialists’ Collaborative Group: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 366:2087–2106. 2005. View Article : Google Scholar : PubMed/NCBI
6	Aebi S, Davidson T and Gruber G: Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6): vi12–vi24. 2011. View Article : Google Scholar : PubMed/NCBI
7	Tazhibi M, Fayaz M and Mokarian F: Detection of prognostic factors in metastatic breast cancer. J Res Med Sci. 18:283–290. 2013.PubMed/NCBI
8	Cadoo KA, Fornier MN and Morris PG: Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 57:312–321. 2013.PubMed/NCBI
9	Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
10	Whale A, Hashim FN, Fram S, Jones GE and Wells CM: Signalling to cancer cell invasion through PAK family kinases. Front Biosci (Landmark Ed). 16:849–864. 2011. View Article : Google Scholar
11	Redig AJ and McAllister SS: Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 274:113–126. 2013. View Article : Google Scholar : PubMed/NCBI
12	Kjoller L and Hall A: Signaling to Rho GTPases. Exp Cell Res. 253:166–179. 1999. View Article : Google Scholar : PubMed/NCBI
13	Bagrodia S and Cerione RA: Pak to the future. Trends Cell Biol. 9:350–355. 1999. View Article : Google Scholar : PubMed/NCBI
14	Szczepanowska J: Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol. 56:225–234. 2009.PubMed/NCBI
15	Edwards DC, Sanders LC, Bokoch GM and Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1:253–259. 1999. View Article : Google Scholar : PubMed/NCBI
16	Martinez A, Walker RA, Shaw JA, Dearing SJ, Maher ER and Latif F: Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features. Mol Pathol. 54:300–306. 2001. View Article : Google Scholar : PubMed/NCBI
17	Killary AM, Wolf ME, Giambernardi TA and Naylor SL: Definition of a tumor suppressor locus within human chromosome 3p21–p22. Proc Natl Acad Sci USA. 89:10877–10881. 1992. View Article : Google Scholar
18	Ma H, Li W and Wu N: Advances in new Nischarin protein. Chinese Pharmacological Bulletin. 26:42010.In Chinese.
19	Alahari SK, Lee JW and Juliano RL: Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration. J Cell Biol. 151:1141–1154. 2000. View Article : Google Scholar : PubMed/NCBI
20	Alahari SK: Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res. 288:415–424. 2003. View Article : Google Scholar : PubMed/NCBI
21	Alahari SK and Nasrallah H: A membrane proximal region of the integrin alpha5 subunit is important for its interaction with nischarin. Biochem J. 377:449–457. 2004. View Article : Google Scholar
22	Ivanov TR, Jones JC, Dontenwill M, Bousquet P and Piletz JE: Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera. J Auton Nerv Syst. 72:98–110. 1998. View Article : Google Scholar : PubMed/NCBI
23	Dontenwill M, Pascal G, Piletz JE, et al: IRAS, the human homologue of Nischarin, prolongs survival of transfected PC12 cells. Cell Death Differ. 10:933–935. 2003. View Article : Google Scholar : PubMed/NCBI
24	Dontenwill M, Piletz JE, Chen M, et al: IRAS is an anti-apoptotic protein. Ann N Y Acad Sci. 1009:400–412. 2003. View Article : Google Scholar
25	Ding Y, Zhang R, Zhang K, et al: Nischarin is differentially expressed in rat brain and regulates neuronal migration. PLoS One. 8:e545632013. View Article : Google Scholar : PubMed/NCBI
26	Baranwal S, Wang Y, Rathinam R, et al: Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. J Natl Cancer Inst. 103:1513–1528. 2011. View Article : Google Scholar : PubMed/NCBI
27	Jain P, Baranwal S, Dong S, Struckhoff AP, Worthylake RA and Alahari SK: Integrin-binding protein nischarin interacts with tumor suppressor liver kinase B1 (LKB1) to regulate cell migration of breast epithelial cells. J Biol Chem. 288:15495–15509. 2013. View Article : Google Scholar : PubMed/NCBI
28	Edge S, Byrd DR, Compton CC, et al: AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: 2010
29	Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 20:3628–3636. 2002. View Article : Google Scholar : PubMed/NCBI
30	Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar : PubMed/NCBI
31	Assoian RK: Anchorage-dependent cell cycle progression. J Cell Biol. 136:1–4. 1997. View Article : Google Scholar : PubMed/NCBI
32	Frisch SM and Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol. 9:701–706. 1997. View Article : Google Scholar : PubMed/NCBI
33	Varner JA, Emerson DA and Juliano RL: Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell. 6:725–740. 1995. View Article : Google Scholar : PubMed/NCBI
34	Zhang Z, Vuori K, Reed JC and Ruoslahti E: The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA. 92:6161–6165. 1995. View Article : Google Scholar : PubMed/NCBI
35	Hu JJ, Lei HT, Hou and YM: A new evaluation method for tumor cell migration process. Chinese Pharmacological Bulletin. 1:128–131. 2010.
36	Alahari SK, Reddig PJ and Juliano RL: The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J. 23:2777–2788. 2004. View Article : Google Scholar : PubMed/NCBI
37	Reddig PJ, Xu D and Juliano RL: Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin. J Biol Chem. 280:30994–31002. 2005. View Article : Google Scholar : PubMed/NCBI
38	Davila M, Frost AR, Grizzle WE and Chakrabarti R: LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem. 278:36868–36875. 2003. View Article : Google Scholar : PubMed/NCBI
39	Yoshioka K, Foletta V, Bernard O and Itoh K: A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA. 100:7247–7252. 2003. View Article : Google Scholar : PubMed/NCBI
40	Bagheri-Yarmand R, Mazumdar A, Sahin AA and Kumar R: LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer. 118:2703–2710. 2006. View Article : Google Scholar
41	Nishita M, Tomizawa C, Yamamoto M, Horita Y, Ohashi K and Mizuno K: Spatial and temporal regulation of cofilin activity by LIM kinase and Slingshot is critical for directional cell migration. J Cell Biol. 171:349–359. 2005. View Article : Google Scholar : PubMed/NCBI
42	Soosairajah J, Maiti S, Wiggan O, et al: Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. EMBO J. 24:473–486. 2005. View Article : Google Scholar : PubMed/NCBI
43	Ding Y, Milosavljevic T and Alahari SK: Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion. Mol Cell Biol. 28:3742–3756. 2008. View Article : Google Scholar : PubMed/NCBI
44	Jackson RJ and Standart N: How do microRNAs regulate gene expression? Sci STKE. 2007:re12007. View Article : Google Scholar : PubMed/NCBI
45	Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF and TNF-α in breast cancer. Cancer Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI